Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease.
Treatment should be initiated only by a physician experienced in the treatment of patients with HDV infection.
Bulevirtide should be administered at 2 mg once daily (every 24 h ± 4 h) by subcutaneous injection as monotherapy or in co-administration with a nucleoside/nucleotide analogue for treatment of underlying HBV infection.
Concerning co-administration with the nucleoside-nucleotide analogues for treatment of HBV infection, refer to section 4.4.
The optimal treatment duration is unknown. Treatment should be continued as long as associated with clinical benefit.
Consideration to discontinue the treatment should be given in case of sustained (6 months) HBsAg seroconversion or loss of virological and biochemical response.
If an injection has been omitted and less than 4 hours have elapsed since the scheduled time, the injection must be performed as soon as possible. The time of the next injection will not be calculated from the time of the “rescue” injection, but according to the injection schedule previously established. It is, therefore, necessary to return to the usual pattern of administration, at the appointed time, the following day.
If an injection has been missed and more than 4 hours have elapsed since the scheduled time, the missed dose should not be administered.
The next injection will take place according to the usual schedule (injection of the prescribed dose without doubling), at the appointed time the next day.
If the injection has been made by mistake more than 4 hours after the scheduled time, the next administration must take place in the usual way (i.e. in accordance with the original schedule).
No data is available in patients >65 years.
No studies have been conducted with bulevirtide in patients with renal impairment. Renal function should be carefully monitored. Elevation of bile salts may occur during treatment. Due to renal excretion of bile salts, elevation of bile salts may be greater in patients with renal impairment.
No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh-Turcotte class A). The safety and efficacy of bulevirtide in patients with decompensated cirrhosis have not been established (see sections 4.4 and 5.2).
The safety and efficacy of bulevirtide in patients younger than 18 years of age have not been established. No data is available.
For subcutaneous use only. Bulevirtide may be injected into sites such as the upper thigh, or abdomen.
Appropriate training should be given to the patients self-administering the product to minimise the risk of the injection site reactions.
The “Instructions for the User”, provided in the carton, must be followed carefully by the patient.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
There are no data on human overdose with bulevirtide. If overdose occurs, the patient must be monitored for evidence of toxicity and given standard supportive treatment as necessary.
24 months.
After reconstitution, chemical and physical in-use stability has been demonstrated for 2 hours at room temperature (up to 25°C). From a microbiological point of view, it is recommended that the product should be used immediately.
Store in a refrigerator (2°C-8°C). In order to protect from light, keep the vials in the outer carton.
Colourless glass vial with bromobutyl rubber stopper, sealed with a flip off cap (aluminium with plastic disc).
Pack-size of 30 vials.
Each vial is intended for single use only and the excess of unused product must be properly disposed of. Water for injections, syringes, needle tips and alcohol wipes should be provided to the patient.
The bulevirtide vial should be taken from the refrigerator shortly before the injection and the blue flipoff cap has to be removed. A single-use syringe should be taken and a needle tip attached to the syringe head in order to extract 1 ml of water for injection into the syringe. The syringe needle with the syringe containing the water for injection should then be inserted into the bulevirtide vial through the rubber stopper. The water for injection inside the syringe will then be injected into the bulevirtide vial and the bulevirtide vial has to be carefully swayed until a clear solution is obtained. The complete content of the bulevirtide vial has to be extracted back into the same syringe with the same needle tip. The needle tip has then to be detached from the syringe. To this syringe, a needle tip for subcutaneous injection has to be attached and any remaining air bubbles have to be removed from the syringe prior to injection. The content of the bulevirtide vial will then by administered subcutaneously. The needle tip has then to be detached from the needle. To this syringe, a special injection needle tip (13 mm, 26 or 27G) has to be attached and any remaining air bubbles have to be removed from the syringe prior injection. The content of the bulevirtide vial will then by administered subcutaneously.
All used components/ waste should be handled according to the current regulation.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
